While i initially didn't like the term of this placement, i can now understand why management decided to go through this path. Probably this was the only way to attract new investors
- The muted response the management got from the market for all the great announcements they made in the last 12 months made.
- I expect they would have the same muted response from market even if they announce a positive study report on "Pivotal US FDA Remplir™ nerve repair status report due in Q1 CY24"
- I am now expecting the release of the report this quarter to be the catalyst to reach a new year high for the share price which will then start to attract more and more interest
While i initially didn't like the term of this placement, i can...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.015(3.85%) |
Mkt cap ! $78.49M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.5¢ | $54.65K | 144.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 44995 | 2 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.5¢ |
Change
-0.015 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 38.0¢ | 38.0¢ | 37.5¢ | 37000 | ||
| Last updated 15.09pm 07/05/2024 ? | |||||
| OCC (ASX) Chart |